-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 22c
-
-
-
-
-
-
-
X4 Pharmaceuticals cuts workforce 50% to save $13 million annually
-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) Presents Positive Phase 2 Chronic Neutropenia Trial Data
-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) PT Lowered to $3 at Stifel
-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on X4 Pharmaceuticals (XFOR)
-
-
-
456,289 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

